An independent committee expresses concern on US efficacy data for AstraZeneca's COVID-19 vaccine; cases of COVID-19 are on the rise in over half of states; wildfire smoke is associated with a significant spike in pediatric respiratory care visits.
As reported by Reuters, the Data Safety Monitoring Board (DSMB), an independent committee overseeing the US trial on the COVID-19 vaccine manufactured by AstraZeneca, has expressed concern that the company may have released outdated information on the trial that would create an incomplete view of the efficacy data. In data unveiled yesterday, AstraZeneca said their vaccine was 79% effective in preventing the virus, with no safety concerns reported. This came after controversy surrounding the vaccine’s unproven links to blood clots in Europe that caused several countries to suspend use.
According to data from Johns Hopkins University, the US 7-day average of daily new cases of COVID-19 are up by at least 5% in 27 states, with a 1% increase nationwide reported after months of rapidly declining case numbers. Reported by CNBC, cases include those of the COVID-19 variant first discovered in the United Kingdom, B117, that some health officials speculate may be the cause of significant case increases in states such as Michigan that reported a 50% increase compared with last week. As vaccination rates rise to about 2.5 million shots per day, testing for COVID-19 has dropped dramatically, suggesting that data may not reflect the true number of cases across the country.
A study published today in Pediatrics found that respiratory care visits among children were associated most prominently with wildfire smoke than other sources of airborne fine particles, even when wildfires were less severe. Reported by STAT, a 10-unit increase of PM2.5, airborne particles less than 2.5 mcm wide from wildfire smoke was linked with a 30% spike in admissions compared with 3.7% from nonsmoke sources. Reasons for pediatric respiratory care visits included asthma, difficulty breathing, respiratory distress, wheezing, and cough.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More